Finotonlimab plus Stapokibart for advanced head and neck cancer
Part of Cancer clinical trials.
This trial tests two drugs, Finotonlimab and Stapokibart, for people with head and neck cancer that has come back or spread to other parts of the body. It may help if you've already tried a PD-1 drug and platinum chemotherapy, but the cancer got worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer (in mouth, throat, or voice box) that has returned or spread.
- You have tried a PD-1 drug with or without platinum chemo, and your cancer got worse within 24 weeks after the last dose.
- You are at least 18 years old and your daily activity level is mild (ECOG 0 or 1).
- You have at least one tumor that can be measured on scans.
- Your blood and organ function tests must meet certain safe levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests a new combination of a drug called finotonlimab (a type of immunotherapy that helps your immune system fight cancer) with chemotherapy for patients with stage II head and neck cancer that has not been treated yet. The treatment is given before and after surgery to see if it can improve outcomes.
This study tests a new drug called stapokibart combined with immune checkpoint inhibitors, which are treatments that help your immune system fight cancer. It is for people with lymphoma that has come back or not responded to previous treatments.
This trial tests a new combination of two drugs (Stapokibart and Tislelizumab) for people with non-small cell lung cancer that has not responded to initial treatment and has no specific gene mutations. The goal is to see if this combo can help when other options have been exhausted.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.